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Death-associated protein kinase 1 has a critical role
in aberrant tau protein regulation and function
BM Kim1, M-H You1, C-H Chen2, S Lee3,4, Y Hong3,4, Y Hong1,3,4, A Kimchi5, XZ Zhou2 and TH Lee*,1
The presence of tangles composed of phosphorylated tau is one of the neuropathological hallmarks of Alzheimer’s disease (AD).
Tau, a microtubule (MT)-associated protein, accumulates in AD potentially as a result of posttranslational modifications, such as
hyperphosphorylation and conformational changes. However, it has not been fully understood how tau accumulation and
phosphorylation are deregulated. In the present study, we identified a novel role of death-associated protein kinase 1 (DAPK1) in
the regulation of the tau protein. We found that hippocampal DAPK1 expression is markedly increased in the brains of AD
patients compared with age-matched normal subjects. DAPK1 overexpression increased tau protein stability and
phosphorylation at multiple AD-related sites. In contrast, inhibition of DAPK1 by overexpression of a DAPK1 kinase-deficient
mutant or by genetic knockout significantly decreased tau protein stability and abolished its phosphorylation in cell cultures and
in mice. Mechanistically, DAPK1-enhanced tau protein stability was mediated by Ser71 phosphorylation of Pin1, a prolyl
isomerase known to regulate tau protein stability, phosphorylation, and tau-related pathologies. In addition, inhibition of DAPK1
kinase activity significantly increased the assembly of MTs and accelerated nerve growth factor-mediated neurite outgrowth.
Given that DAPK1 has been genetically linked to late onset AD, these results suggest that DAPK1 is a novel regulator of tau
protein abundance, and that DAPK1 upregulation might contribute to tau-related pathologies in AD. Therefore, we offer that
DAPK1 might be a novel therapeutic target for treating human AD and other tau-related pathologies.
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Tau-related pathology (tauopathy) is involved in neurodegen-
erative diseases, including Alzheimer’s disease (AD) and
related disorders.1–4 In these diseases, tau is commonly
hyperphosphorylated on serine or threonine residues prior
to tangle formation and neurodegeneration.5–7 Tau helps
stabilize the microtubule (MT) network in neurons,8–11 and
aberrant tau phosphorylation disrupts its MT function12–14 and
alters its protein stability.15–19 In all tauopathies, aberrantly
phosphorylated tau adopts abnormal conformations
and aggregates into neurofibrillary tangles (NFTs).5–7
The significance of tau phosphorylation is further supported
by the findings that tau kinases20–22 or phosphatases23,24 are
deregulated in AD and that their modulation can affect
tauopathies.25–27 However, how tau accumulation and phos-
phorylation are deregulated in neurodegenerative diseases,
such as AD, is not fully understood.
Death-associated protein kinase 1 (DAPK1), a death
domain-containing calcium/calmodulin-regulated serine/
threonine kinase, functions as a positive mediator of
apoptosis.28 DAPK1 overexpression promotes neuronal cell
death, and neurons lacking DAPK1 are less susceptible to
apoptotic insults in cell culture and knockout (KO) animal
models.28 Furthermore, DAPK1 regulates tau toxicity by
modulating MT assembly and neuronal differentiation,29 and
influences brain damage via the N-methyl-D aspartate
receptor in stroke.30 Moreover, genome-wide association
study showed that two gene-centric single-nucleotide poly-
morphisms in the DAPK1 are strongly associated with late-
onset AD.31,32 Indeed, mice expressing DAPK1 kinase
domain deletions showed enhanced learning and spatial
memory compared with wild-type (WT) mice.33 However, the
association between DAPK1 and late-onset AD has not been
sufficiently explored, as little is known about the downstream
targets of DAPK1 in AD, and DAPK1 regulation in AD
progression is poorly understood.
We showed previously that DAPK1 phosphorylates Ser71
in the catalytic active site of Pin1, thereby inhibiting its cellular
function.34 Pin1, a unique peptidyl-prolyl cis–trans isomerase,
is an enzyme that has a critical role in regulating a subset of
phosphoproteins by specifically catalyzing conformational
change on the phosphorylated Ser/Thr-Pro motifs.35,36 In line
with its diverse physiological role, Pin1 has been linked to the
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pathogenesis of various human diseases, including AD,
Parkinson disease, cancer, and asthma.35,36 Moreover, Pin1
has an important protective role in the brain against AD by
maintaining tau and amyloid precursor protein in their proper
forms.37–40 Pin1 is also colocalized with phosphorylated tau in
AD brain and other tauopathies.41 It binds to and isomerizes
the pThr231-Pro motif in tau to restore its ability to bind MTs
and to promote their assembly.40 Therefore, loss of Pin1
function can lead to abnormal tau protein accumulation and
MT disintegration, which are the main features of AD.
Although DAPK1 inhibits the tumorigenic properties of Pin1,
it is not known whether DAPK1 regulates Pin1 function during
neurodegeneration.
In this study, we found that DAPK1 enhanced tau stability
and phosphorylation, thereby inhibiting its cellular function.
Furthermore, we showed that DAPK1-dependent tau regula-
tion might be mediated by Pin1 Ser71 phosphorylation and
subsequent inactivation. Taken together, these results
demonstrate for the first time a potential role for DAPK1 in
the regulation of tau accumulation and function in neuro-
degenerative diseases, including AD.
Results
DAPK1 expression is highly upregulated in human AD
hippocampus. As DAPK1 polymorphisms are associated
with AD susceptibility,31,32 we first investigated potential
association between late onset AD and DAPK1 expression.
Considering DAPK1 expression is restricted to the hippo-
campus of the adult brain,42 hippocampal DAPK1 levels were
measured in a cohort of 12 AD patients and 12 age-matched
normal subjects. The expression of DAPK1 was found to
increase more than two-fold in the AD patients compared
with that of normal subjects (Figures 1a and b). Moreover,
phosphorylated Thr231 or Ser396 of tau was highly over-
expressed in the brains of AD patients, as describe
previously (Figure 1a).12,43 DAPK1 mRNA levels were also
increased in AD brains compared with normal brains, but this
difference was not statistically significant, implying that
DAPK1 upregulation in AD is a consequence of increased
translation and/or stability of the DAPK1 protein (Figure 1c).
Thus, these results showed that in human AD brains DAPK1
was upregulated, and this might be correlated with tau
phosphorylation.
DAPK1 increases tau protein expression and stability in
cells. To examine whether DAPK1 contributes to age-
dependent neurodegeneration in AD via tau regulation, we
determined the effect of DAPK1 on tau protein expression.
DAPK1 significantly increased exogenous tau protein levels
compared with the vector control (Figure 2a). We further
examined tau protein expression using DAPK1 mutants,
which have been characterized previously.44 DAPK1K42A,
a kinase-deficient mutant, downregulated, whereas
DAPK1DCaM, a constitutively active mutant, upregulated
exogenous tau protein expression compared with the vector
control (Figure 2a). Endogenous tau expression was
assessed in human neuroblastoma SH-SY5Y cells trans-
fected with the vector control, DAPK1, DAPK1K42A, or
DAPK1DCaM and was found to be upregulated in DAPK1-
and DAPK1DCaM-expressing cells compared with the vector
control- or DAPK1K42A-expressing cells (Figure 2b). Similar
trends were observed in another neuroblastoma cell line,
SK-N-SH (Supplementary Figure 1). Next, we efficiently
knocked down the expression of endogenous DAPK1 using
lentiviral-mediated small hairpin RNAs (sh-RNAs) or small
interfering RNAs (si-RNAs) in the SH-SY5Y cells (Figures 2c
and d). In contrast with the control cells, endogenous tau
expression was decreased dramatically in DAPK1 knock-
down cells (Figures 2c and d). However, there was no
increase in tau mRNA levels after overexpression of DAPK1
or DAPK1K42A (Figure 2e), suggesting that DAPK1 does not
affect tau at the level of transcription but rather at the protein
level. Thus, DAPK1 increases exogenous and endogenous
tau protein expression in cells.
Given that DAPK1 increased tau protein levels but not
transcription, the next question was whether DAPK1 might
affect tau protein stability. The exogenous- and endogenous
tau protein were quite stable in cells expressing DAPK1 or
DAPK1DCaM but not DAPK1K42A, compared with cells expres-
sing the vector control (Figures 3a, b, e and f). We also used
lentiviral expression systems to generate NIH3T3 cells
expressing DAPK1 in a tetracycline-inducible manner, as
described:34 the addition of the tetracycline analoge, doxycy-
cline, into the growth medium resulted in the production of
DAPK1 (Supplementary Figure 2). Doxycycline-induced
expression of DAPK1 efficiently enhanced tau protein stability
compared with the vector control (Figures 3c and d).
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Figure 1 DAPK1 expression is increased in the AD patient brain. Hippocampal
tissues of 12 AD patients and 12 age-matched controls were harvested. (a) Proteins
from normal and AD hippocampus were used for immunoblot with anti-DAPK1, anti-
pT231-Tau, anti-pS396-Tau, or anti-actin antibody. The blots are representative of
three independent experiments. (b) DAPK1 intensities were quantified by computer-
assisted densitometry (*Po0.05 versus normal control; ANOVA/Dunnett’s test).
(c) Quantitative RT-PCR was performed on cDNA samples to measure human
DAPK1 mRNA. Eight AD and six normal brain samples with short PMI (o20 h) were
used to minimize possible RNA degradation. 18S ribosomal RNA was used as
an endogenous control. Each data point represents the mean±S.E. of three
independent experiments
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Altogether, these results suggest that DAPK1 overexpression
inhibits tau protein turnover in cells.
DAPK1 regulates tau stability through Thr231 phosphor-
ylation. Recent studies by our group and others reported
that Pin1 regulates tau phosphorylation, protein stability,
function and tauopathy37,38,40 and that DAPK1 negatively
regulates Pin1 activity through Ser71 phosphorylation.34 It
was also shown that the MT-affinity regulating kinase
(MARK) 1/2 is activated by DAPK1 to phosphorylate tau on
Ser262, regulating its toxicity.29 To examine whether
DAPK1-enhanced tau stability is dependent upon the
inhibition of Pin1 and/or the activation of MARK1/2, we
generated tau point mutations, tauT231A, which is unable to
bind Pin1, and tauS262A, which is resistant to MARK1/2
phosphorylation. When the T231A tau mutant was co-
transfected with DAPK1 or the vector control, tauT231A
expression levels were not increased in DAPK1-expressing
cells compared with the vector control (Figure 4a). Moreover,
the stability of T231A tau protein was not affected by either
DAPK1 or DAPK1K42A (Figures 4b and c), suggesting that
Pin1 action on phosphorylated Thr231 is necessary for
DAPK1-regulated tau protein stability. However, expression
and stability of the S262A protein were increased by DAPK1
expression, but not by DAPK1K42A, compared with the vector
control (Figures 4d–f), similar to the results with the WT tau
protein. These results indicate that MARK proteins are not
involved in the effects of DAPK1 on tau protein stability.
Taken together, our data show that DAPK1 regulates tau
protein expression and stability, presumably through tau
Thr231 and Pin1 phosphorylation.
DAPK1 increases tau protein stability by inhibiting Pin1
function. We further investigated the role of Pin1 by
examining tau protein turnover using DAPK1 KO and Pin1
KO mouse embryonic fibroblast (MEF) cells, which were
confirmed for the absence of DAPK1 and Pin1 protein,
respectively (Supplementary Figure 3). When we transfected
WT tau into DAPK1 KO or WT MEF cells, the exogenous tau
protein was less stable in DAPK1 KO than in WT MEF cells
(Figures 5a and b). However, when we co-transfected
tau with vector control or DAPK1 into Pin1 KO MEF
cells, exogenous tau protein stability did not increase in
DAPK1-transfected cells compared with vector controls
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Figure 2 DAPK1 increases tau protein expression in cell culture models. (a) HeLa cells were co-transfected with pcDNA3-Tau and either pRK5-Flag, pRK5-Flag-DAPK1,
pRK5-Flag-DAPK1K42A or pRK5-Flag-DAPK1DCaM for the indicated times. The cell lysates were subjected to western blot analysis with anti-Tau-5 or anti-tubulin antibody. The
blots are representative of three independent experiments. (b) SH-SY5Y cells were transfected with pRK5-Flag, pRK5-Flag-DAPK1, pRK5-Flag-DAPK1K42A or pRK5-Flag-
DAPK1DCaM for the indicated times. The cell lysates were subjected to western blot analysis with anti-Tau-5 or anti-tubulin antibody. The blots are representative of three
independent experiments. (c) SH-SY5Y cells were infected with control lentiviral vector (pLKO.1) or vectors encoding two DAPK1-specific sh-RNAs, and selected using
puromycin (1.5mg/ml) for 36 h. The cell lysates were subjected to western blot analysis with anti-Tau-5 or anti-tubulin antibody. The blots are representative of three
independent experiments. (d) SH-SY5Y cells were transfected with two different human DAPK1-sepcific si-RNAs or scrambled control si-RNA for 36 h. The cell lysates were
subjected to western blot analysis with anti-Tau-5 or anti-tubulin antibody. The blots are representative of three independent experiments. (e) SH-SY5Y cells were transfected
with pRK5-Flag, pRK5-Flag-DAPK1, or pRK5-Flag-DAPK1K42A for 24 h. Quantitative RT-PCR was performed on cDNA samples to measure human tau mRNA, and the 36B4
gene was used as an endogenous control. Each data point represents the mean±S.E. of three independent experiments
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Figure 3 DAPK1 increases tau protein stability in cell culture models. (a, b) HeLa cells were co-transfected with pcDNA3-Tau and either pRK5-Flag, pRK5-Flag-DAPK1,
pRK5-Flag-DAPK1K42A or pRK5-Flag-DAPK1DCaM for 20 h followed by treatment with 10mg/ml CHX for the indicated times. The cell lysates were subjected to western blot
analysis with anti-Tau-5 or anti-actin antibody. The blots are representative of three independent experiments, and data shown represent means±S.E. of three independent
experiments (*Po0.05 versus vector-expressing control; ANOVA/Dunnett’s test). (c, d) NIH3T3 cells stably expressing pTRE-Tight vector or pTRE-Tight-DAPK1 were
transfected with pcDNA3-Tau for 8 h followed by treatment with 2 mg/ml doxycycline for 14 h. Doxycycline-induced cells were treated with 25 mg/ml CHX for the indicated times.
The cell lysates were subjected to western blot analysis with anti-Tau-5, anti-DAPK1 or anti-actin antibody. The blots are representative of three independent experiments, and
data shown represent means±S.E. of three independent experiments (*Po0.05 versus Tight-vector-expressing control; ANOVA/Dunnett’s test). (e, f) SK-N-SH cells were
transfected with pRK5-Flag, pRK5-Flag-DAPK1, pRK5-Flag-DAPK1K42A or pRK5-Flag-DAPK1DCaM for 20 h followed by treatment with 75mg/ml CHX for the indicated times.
The cell lysates were subjected to western blot analysis with anti-Tau-5 or anti-actin antibody. The blots are representative of three independent experiments, and data shown
represent means±S.E. of three independent experiments (*Po0.05 versus vector-expressing control; ANOVA/Dunnett’s test)
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Figure 4 Effects of DAPK1 on protein stability of tau T231A and S262A mutants. (a, d) HeLa cells were co-transfected with pcDNA3-T231A tau and either pRK5-Flag or
pRK5-Flag-DAPK1 (a) or co-transfected with pcDNA3-S262A tau and either pRK5-Flag or pRK5-Flag-DAPK1 (d) for the indicated times. The cell lysates were subjected to
western blot analysis with anti-Tau-5 or anti-tubulin antibody. The blots are representative of three independent experiments. (b, c, e, f) HeLa cells were co-transfected with
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(Figures 5c and d). In addition, sh-RNA-mediated stable
knockdown of Pin1 also abrogated DAPK1-enhanced tau
stability in HeLa cells (Supplementary Figure 4), indicating
that Pin1 has an important role in DAPK1-mediated tau
protein regulation. Next, to determine whether DAPK1
inhibits tau turnover by Pin1, we used NIH3T3 cells stably
expressing Pin1 and tetracycline-inducible DAPK1,
DAPK1K42A or the vector control as shown previously.34
Tau protein stability and Pin1 Ser71 phosphorylation were
significantly increased in cells expressing DAPK1/Pin1, but
not DAPK1K42A/Pin1, compared with the vector control/Pin1-
expressing cells (Figures 5e and f). As Pin1 may promote tau
degradation, these results suggest that DAPK1 acts as a
central regulator of tau protein stability via Pin1 inhibition.
DAPK1 KO mice show reduced tau protein expression
and stability. We next examined the effects of DAPK1 on
tau protein expression and stability in the brains of age-
matched WT and DAPK1 KO mice at different ages.
Whereas levels of doublecortin (DCX), an established
neurogenesis marker, decreased with age in both mouse
models, the expression of DAPK1 was not affected in WT
mice (Figure 6a). We next evaluated endogenous tau protein
expression in these mice. Whereas there was no significant
difference in tau expression between 1- and 6-month-old WT
and KO mice (Figure 6b), it was significantly decreased in 12-
and 22-month-old DAPK1 KO mice compared with WT mice
of the same age (Figures 6b and c). There were no significant
differences in mouse tau mRNA levels between WT and
DAPK1 KO mice at 12 or 22 months (Figure 6d), confirming
the results shown in Figure 2e. These findings suggest that
DAPK1 KO downregulates tau protein expression in an
age-dependent manner in the mouse brain.
Next, we examined whether DAPK1 affects tau protein
stability in brain tissues. In primary cortical neurons, the half-
life of endogenous mouse tau was B20 h in the presence of
DAPK1 but was decreased significantly to o3 h in the
absence of DAPK1 (Figures 6e and f). Moreover, phosphor-
ylation of Pin1 on Ser71 was also higher in cortical neurons
from WT mice than those from DAPK1 KO mice (Figure 6e),
suggesting that DAPK1-mediated Pin1 phosphorylation is
correlated with tau stability. In brain slices from 1-month-old
WT and DAPK1 KO mice, the half-life of tau wasB20 h in the
presence of DAPK1 and was decreased dramatically toB6 h
in the absence of DAPK1 (Figures 6g and h). We obtained the
same results in brain slices from 6-month-old mice
(Supplementary Figure 5). Thus, these results showed that
DAPK1 enhanced endogenous tau stability in primary cortical
neurons as well as brain-slice cultures, an in situ model
resembling and retaining many organizational features of
living brain tissue.
DAPK1 affects tau phosphorylation in an age-dependent
manner. Tau protein is aberrantly phosphorylated, adopts
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Figure 5 DAPK1 increases tau protein stability through the inhibitory phosphorylation of Pin1. (a, b) MEF cells from WT and DAPK1 KO mice were transfected with
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independent experiments. (e, f) NIH3T3 cells stably expressing Flag-Pin1 in combination with doxycycline-inducible expression of pTRE-Tight (‘Vectorþ Pin1’) or pTRE-Tight-
DAPK1 (‘DAPK1þPin1’) or pTRE-DAPK1K42A (‘K42Aþ Pin1’) were transfected with pcDNA3-Tau for 8 h and subsequently induced with 2mg/ml doxycycline for an
additional 14 h followed by treatment with 25 mg/ml CHX for the indicated times. The cell lysates were subjected to western blot analysis with anti-Tau-5, anti-Flag, anti-pSer71-
Pin1, or anti-actin antibody. The blots are representative of three independent experiments, and data shown represent means±S.E. of three independent experiments
(*Po0.05 versus vectorþ Pin1-expressing control; ANOVA/Dunnett’s test)
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abnormal conformations, and aggregates into fibrils during
all tauopathies, including AD.5–7 As shown in Figure 7a,
compared with the vector control, DAPK1, but not
DAPK1K42A, increased the phosphorylation of exogenous
tau protein in HeLa cells, as detected by Thr231-specific
(AT180), Ser262-specific, and Ser396-specific (PHF-13)
antibodies that recognize specific tau phosphoepitopes
and/or abnormal conformations specific to AD NFT. DAPK1
also triggered the phosphorylation of endogenous tau protein
in SH-SY5Y cells (Figure 7b). Moreover, DAPK1 induced
Ser71 phosphorylation of Pin1 compared with cells trans-
fected with the empty vector or DAPK1K42A, suggesting that
enhanced expression and phosphorylation of tau in DAPK1-
expressing cells was due to phosphorylation of Pin1
(Figures 7a and b). Thus, DAPK1 overexpression, but not
the kinase-deficient mutant K42A, increased tau phosphor-
ylation in cells.
The effect of DAPK1 ablation on phosphorylation of tau and
Pin1 in mouse brain tissue was evaluated using
immunoblotting with AT180, pSer262-specific, PHF-13, and
pSer71-Pin1 antibodies. DAPK1 KO significantly decreased
the levels of tau phosphorylation as well as Pin1 phosphor-
ylation in the brains of DAPK1 KO mice at age 12–22 months,
but not those at age 6 month, compared with WT littermates
(Figure 7c). The inhibitory effects of DAPK1 ablation on tau
phosphorylation were also observed when we analyzed the
sarkosyl-insoluble fraction. Total and phosphorylated tau
levels were barely detectable in the sarkosyl-insoluble fraction
at 6 month, but mildly expressed at 12–22 months of age in
WT mice (Figure 7d). However, levels of total and phosphory-
lated tau were significantly reduced in DAPK1 KO mice at
12–22 months of age compared with those in WT mice
(Figure 7d). Our immunohistochemical staining also
confirmed that DAPK1 ablation reduced pThr231-Tau and
pSer71-Pin1 levels in mouse brain sections (Figures 7e and f).
Thus, our results indicate that DAPK1 KO dramatically
decreased tau phosphorylation in whole-brain lysates and
inhibited tau-related pathological phenotypes such as NFT
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Figure 6 DAPK1 KO reduces tau protein expression and stability in mouse brain. (a) Whole-brain lysates from mice harvested at the indicated age (in months) were
analyzed for DAPK1 levels. (b) The brain tissues were homogenized and subjected to western blot analysis with anti-Tau-5 or anti-actin antibody. (c) Densitometric analysis of
normalized levels of tau using actin as a loading control obtained from 12- and 22-month-old mice. (d) Six brain tissue sections of WT and DAPK1 KO mice, 12- or 22-month-
old, were harvested. Quantitative RT-PCR was performed on cDNA samples to measure mouse tau mRNA, and the 36B4 gene was used as an endogenous control. (e, f)
Primary cortical cultures derived from the cerebral cortex of embryonic day 16 (E16) WT and DAPK1 KO mice were treated 25 mg/ml of CHX for indicated times. Cells were
lysed and subjected soluble protein lysates to western blot analysis with anti-Tau-5, anti-Pin1, anti-pSer71-Pin1, or anti-actin antibody. (g, h) Brain tissue slices of 260mm were
prepared and cultured from WT or DAPK1 KO mice at 1 month of age. 35 mg/ml of CHX was added and chased for indicated times. Some brain tissue slices were cultured for
24 h without CHX to monitor structural integrity (last 2 columns). Brain slices were lysed and subjected soluble protein lysates to western blot analysis with anti-Tau-5 or
anti-actin antibody. All of above blots are representative of three independent experiments, and data shown represent means±S.E. of three independent experiments
(*Po0.05 versus WT; ANOVA/Dunnett’s test)
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conformations in sarkosyl-insoluble fraction in an age-
dependent manner in the mouse brain model.
DAPK1 inhibits neurite outgrowth and MT assembly.
Tau has an important role in regulating MT dynamics8–11 and
neuronal differentiation,45 which are modulated by site-
specific phosphorylation.46 Considering the effects of DAPK1
on Pin1-mediated tau protein stability and phosphorylation,
we addressed the biological significance of DAPK1 on tau
function by assaying neurite outgrowth and MT assembly.
Inhibition of DAPK1 using either novel selective DAPK1
inhibitor (IC50¼ 69 nM) or RNA interference significantly
increased NGF-induced neurite outgrowth in PC12 cells
(Figures 8a–e, Supplementary Figure 6) and enhanced
maturation of primary mouse cortical neurons
(Supplementary Figure 7). As the primary function of tau is
modulation of cytoskeletal MT stability and function,8–11 and
abnormal tau phosphorylation results in disruption of MT
organization,12–14 we also investigated the effect of DAPK1
on MT organization. DAPK1 inhibitor significantly increased
the protein levels of polymerized tubulin showing similar
effects induced by MT-stabilizing paclitaxel (Figures 8f and
g). However, MT-disrupting nocodazole caused inhibition of
tubulin polymerization (Figures 8f and g). Therefore, our
results suggest that DAPK1 inhibits neuronal differentiation
and MT polymerization by affecting tau functions.
Discussion
Although there are several current evidence for a role of
DAPK1 in neurodegenerative disorders,29,31–33 little has been
known about the molecular mechanisms through which
DAPK1 exerts this effect. Here, we show that DAPK1 is
associated with tau-mediated neuronal degeneration by
enhancing tau stability and aberrant phosphorylation, leading
to deregulation of its MT binding and polymerization functions.
Enhanced protein stability and/or decreased degradation of
tau trigger its aggregation, which inhibits neuronal cell survival
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Figure 7 DAPK1 increases tau phosphorylation and formation of sarkosyl-insoluble tau aggregates. (a) HeLa cells were co-transfected with pcDNA3-Tau and either
pRK5-Flag, pRK5-Flag-DAPK1, or pRK5-Flag-DAPK1K42A for the indicated times. The cell lysates were subjected to western blot analysis for the phosphorylation of
exogenous tau protein. Anti-tubulin antibody was used as a loading control. The blots are representative of three independent experiments. (b) SH-SY5Y cells were
transfected with pRK5-Flag or pRK5-Flag-DAPK1 for the indicated times. The cell lysates were subjected to western blot analysis for the phosphorylation of endogenous tau
protein. Anti-tubulin antibody was used as a loading control. The blots are representative of three independent experiments. (c, d) The whole-cell lysates (c) and sarkosyl-
insoluble fractions (d) were subjected to western blot analysis. Phospho-specific tau antibodies (AT180, Ser262 and PHF-13) were used to detect tau phosphorylation. The
blots are representative of three independent experiments. (e, f) Immunohistochemistry of paraffin-embedded brain sections from WT and DAPK1 KO mice at 24-month-old,
comparing the levels of phosphorylated tau (Thr231) and phosphorylated Pin1 (Ser71). Original magnification,  40 (main photographs);  60 (insets); Scale bar¼ 100mm.
The images are representative of three independent experiments, and data shown represent means±S.E. of three independent experiments (*Po0.05 versus WT;
ANOVA/Dunnett’s test)
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and induces neurodegeneration.12–16,18,19 Several proteins
have been known to regulate tau protein stability. For
example, Pin1 knockdown and/or downregulation in AD
neurons increase tau protein stability.38 As DAPK1 was
shown to inhibit Pin1 catalytic activity and function,34 DAPK1
could affect tau via Pin1 inhibition in neurons.
Our greatest interest was in the potential association
between late onset AD and DAPK1 expression, as DAPK1
polymorphisms are associated with AD susceptibility.31,32 We
measured DAPK1 expression in the hippocampus of AD
patients and normal controls, as the hippocampus is damaged
early and severely in AD compared with other parts of the
cortex and DAPK1 expression is restricted to the hippocam-
pus of the adult brain.42 We found that hippocampal tissues
from aged AD brains had increased levels of DAPK1 protein
relative to age-matched normal subjects.
We found that the DAPK1 significantly enhanced tau
protein expression and stability in cell culture and mouse
brain models. Moreover, DAPK1K42A, a kinase-deficient
DAPK1 mutant, could not enhance tau protein stability,
suggesting that DAPK1 kinase activity is critical for tau protein
stability. It was shown that the levels of neurofilament (NF)
protein are increased significantly in AD47,48 and that WW
domain-containing oxidoreductase (WWOX) is downregu-
lated in the neurons of AD hippocampi.49 Interestingly,
DAPK1 had no effect on the NF light chain (NF-L) but
significantly downregulated WWOX protein levels (data not
shown), which remains to be further elucidated.
Abnormal phosphorylation of tau is considered to be one of
the earliest events in neuronal degeneration and appears to
precede tau aggregation.5–7 This abnormal phosphorylation
results not only in a toxic loss of function, such as decreased
MT binding, but also a toxic gain of function, such as increased
tau–tau interaction and pathological aggregation of PHFs.46
Phosphorylation can also alter the stability and proteotoxicity
of tau.15,16,18,19 In cell cultures, DAPK1, but not the kinase-
deficient mutant K42A, increased tau phosphorylation at
Thr231, Ser262, and Ser396. These results were confirmed in
the mouse brain model, suggesting that DAPK1 KO
decreased tau phosphorylation at AD-related sites. Interest-
ingly, the expression of total and phosphorylated tau in
DAPK1 KO mouse brain decreased in an age-dependent
manner with changes more prominent in 12- to 22-month-old
mice. The sarkosyl-insoluble fractions were enriched for
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Figure 8 DAPK1 inhibits neurite outgrowth and MT assembly. (a, b) After serum starvation (0.5% horse serum and 0.25% FBS) for 12 h, PC12 cells were pretreated with
100 nM DAPK1 inhibitor for 2 h prior to the co-treatment with NGF (50 ng/ml). After NGF treatment for up to 50 h, the level of neurite outgrowth was quantified by counting the
number of PC12 cells bearing neurites and measuring the neurite length in ten random images from triplicate experiments. The representative images are shown, and data
represent means±S.E. of three independent experiments (*Po0.05 versus DMSO; ANOVA/Dunnett’s test). Distribution of the neurite length was quantified as described in
the ‘Materials and Methods’ section. (c, d) PC12 cells were transfected with rat DAPK1 si-RNA or scrambled si-RNA for 36 h and serum-deprived for 12 h followed by NGF
(50 ng/ml) treatment. After NGF treatment for up to 50 h, the level of neurite outgrowth was quantified as described in Figure 8b. The representative images are shown, and
data represent means±S.E. of three independent experiments (*Po0.05 versus si-Control; ANOVA/Dunnett’s test). (e) The efficiency of a si-RNA-mediated knockdown of
DAPK1 in PC12 cells. (f, g) PC12 cells were treated with the vehicle (DMSO), paclitaxel (0.2mM, Pacli), nocodazole (2mM, Noco) or DAPK1 inhibitor (70-, 100 nM) for 12 h and
then lysed with hypotonic buffer. Equal amounts of cytosolic (S, soluble) and cytoskeletal (P, polymerized) proteins were separated by SDS-PAGE and immunoblotted with
anti-tubulin antibody. Tubulin expression level at DMSO-treated cytosolic/soluble fraction was arbitrarily defined as ‘10’. The representative blots are shown, and data
represent means±S.E. of three independent experiments. Statistical differences between the level of soluble and polymerized tubulin in each treatment were also determined
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abnormal fibrils and phosphorylated tau.50 Sarkosyl-insoluble
tau, which provides a measure for abnormal tau aggrega-
tion,51 was barely detected in 6-month-old WT mouse brains
and was found in moderate levels in 12- to 22-month-old mice.
Both phosphorylated and total tau levels in the sarkosyl-
insoluble fraction were significantly reduced in DAPK1 KO
mice compared with WT littermates. These results suggest
that DAPK1 is involved in the pathological transition from the
normal soluble to the filamentous insoluble form of tau.
Given that aberrant tau phosphorylation disrupts its MT
function12–14 and DAPK1 affected tau phosphorylation,
DAPK1 potentially alters tau-MT interaction. We showed that
inhibition of DAPK1 promoted NGF-induced neurite out-
growth, a major indicator of overall nervous system cellular
health. Tau drives neurite outgrowth and elongation by
promoting the assembly of tubulin into MT,8–11 which are
critical for the establishment of neuronal cell polarity.8,52 Our
results also demonstrated that the inhibition of DAPK1 kinase
activity led to an increased assembly of tubulin into MTs,
suggesting that DAPK1 suppresses neurite outgrowth and MT
assembly via abnormal phosphorylation of tau.
Pin1 has a pivotal role in protection against neurodegen-
eration by restoring the conformation and function of
phosphorylated tau or by promoting its dephosphoryla-
tion.36–38,40 One of our primary interests was the involvement
of Pin1 in DAPK1-mediated tau protein regulation, as it was
shown that DAPK1 phosphorylated Ser71 in the catalytic site
and inhibited the cellular function of Pin1.34 DAPK1-mediated
increase in tau protein expression and stability were accom-
panied by increased Pin1 Ser71 phosphorylation. DAPK1 did
not increase the stability of the T231A tau mutant, which was
also unaffected by Pin1. In a similar fashion, DAPK1 did not
affect tau protein stability in Pin1 KO MEF cells. These results
are in line with immunohistochemical data showing that the
expression of Ser71 phosphorylated Pin1 was significantly
lower in DAPK1 KO mouse brain compared with WT mouse
brain. Altogether, these data suggest that DAPK1 regulates
tau protein via inhibitory phosphorylation of Pin1.
Recently, Wu et al 29 reported that MARK1/2 is important in
DAPK1-mediated MT assembly and tau toxicity. Ser262 of tau
is the most important residue phosphorylated by MARK2 for
MT dynamics53,54 and that phosphorylation of this residue is
enhanced in AD, which may have a role in tangle forma-
tion.55,56 The interaction between MARK2 and tau has also
been investigated extensively.56 We demonstrated that the
protein expression and stability of the S262A tau mutant,
which inhibits the interaction between MARK2 and tau, were
significantly increased by DAPK1, similar to that of WT tau,
suggesting that DAPK1-enhanced tau protein stability is
independent of MARK proteins.
As tau accumulation is a critical event in tauopathy, our
demonstration of the critical role of DAPK1 in tau accumula-
tion substantiates the need for further studies on its effects on
tauopathy. Such an effort would benefit from the generation of
transgenic (Tg) mice with inducible and brain-restricted
DAPK1 expression or of DAPK1 KO/ Tg mice crossed with
tauopathy mouse models. Because AD is an irreversible and
progressive brain disease, slowing its progression is currently
the best option, underscoring the importance of early
diagnosis and therapeutic intervention for improving
treatment outcome. Even though we detected increased
DAPK1 expression in the brains of AD patients, it has not yet
been determined whether it is a reliable biological diagnostic
marker for the incipient stages of AD. Standard laboratory
testing, such as blood tests, combined with the newly
developed and state-of-the-art brain molecular imaging
techniques used to detect brain pathological biomarkers will
facilitate investigation of this possibility.
Taken together, our findings suggest that DAPK1 enhances
tau protein stability and that DAPK1 KO might abolish
abnormal phosphorylation and aggregation of tau. We also
found that DAPK1 triggered Pin1 Ser71 phosphorylation in a
neuronal model, and DAPK1-mediated regulation of tau
protein was prevented in the absence of Pin1, suggesting a
critical role for Pin1. The functional studies showed that
DAPK1 is involved in the impairment of normal cellular tau
function, including MT assembly. Furthermore, our results
also demonstrated that DAPK1 expression is increased in AD
brains and may be a marker of AD pathology. Overall, our data
suggest a model in which DAPK1 inhibits tau function via
aberrant tau phosphorylation/accumulation followed by
impaired tau-MT interactions and promote pathological tau
aggregation through inhibitory phosphorylation of Pin1
(Supplementary Figure 8). Moreover, our studies suggest
that DAPK1 represents a potential novel therapeutic approach
for human AD and other tauopathies.
Materials and Methods
Materials. Cycloheximide (CHX), N-lauroylsarcosine Sodium Salt, nerve growth
factor (NGF), paclitaxel, nocodazole, and paraformaldehyde (PFA) were
purchased from Sigma (St. Louis, MO, USA). DAPK1 inhibitor (4Z)-4-(3-
Pyridylmethylene)-2-styryl-oxazol-5-one was obtained from Calbiochem (Billerica,
MA, USA). CHX was used to inhibit protein synthesis and assess tau protein
stability. The alkyl anionic detergent N-lauroylsarcosine sodium salt was used to
obtain sarkosyl-insoluble fraction. NGF was used to stimulate neurite outgrowth.
Paclitaxel was used to stabilize MT, and Nocodazole was used to disrupt MT.
(4Z)-4-(3-Pyridylmethylene)-2-styryl-oxazol-5-one was used to specifically inhibit
DAPK1 kinase activity.
Cell culture. The human cervix carcinoma cell line HeLa; the human
neuroblastoma cell lines SH-SY5Y and SK-N-SH; the mouse fibroblast cell line
NIH3T3; and the rat pheochromocytoma cell line PC12 were obtained from the
American Type Culture Collection. MEF cells were obtained from the WT, DAPK1
KO, and Pin1 KO embryos between embryonic day 12.5 and 14.5. HeLa,
SH-SY5Y, SK-N-SH, NIH3T3, and MEF cells were cultured in high-glucose
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin (all from
Gibco, Grand Island, NY, USA). PC12 cells were cultured in DMEM high-glucose
supplemented with 10% horse serum and 5% FBS, 100 U/ml penicillin, and
100mg/ml streptomycin (all from Gibco). The cultures were maintained at 37 1C
under 5% CO2.
Plasmid transfection. The cDNA fragment encoding the human DAPK1 or
DAPK1K42A mutant (in which lysine 42 was replaced by alanine) or DAPK1DCaM
mutant (in which a Ca2þ /Calmodulin regulatory domain is deleted) was cloned
into 50-end-Flag tagged and CMV promoter-driven mammalian expression vector
pRK5. The full-length cDNA of human WT tau or T231A (in which threonine 231
was replaced by alanine) tau or S262A (in which serine 262 was replaced by
alanine) tau was cloned in the mammalian expression vector pcDNA3.1 vector
(Invitrogen, Grand Island, NY, USA). Cells were transiently transfected with
different plasmids using Lipofectamine 2000 (for HeLa, SH-SY5Y, SK-N-SH, and
NIH3T3) or Lipofectamine LTX&Plus (for MEF and PC12) transfection reagent
(Invitrogen) according to the manufacturer’s instruction.
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Lentiviral infection and si-RNA transfection. For generating stable
DAPK1 knockdown SH-SY5Y cells, two DAPK1 sh-RNA clones, which are
constructed within lentiviral pLKO.1-Puro vector were transfected together with
VSV-G- and gag-pol-expressing plasmids into 293T cells. Sixty hours after
transfection, virus-containing supernatants were used to infect the SH-SY5Y
cells. A day after infection, the stable clones were selected using 1.5mg/ml
puromycin. The target sequences of DAPK1-specific sh-RNAs were as follows:
sh-RNA-#1, 50-CAAGAAACGTTAGCAAATG-30; sh-RNA-#2, 50-GGTCAAGGAT
CCAAAGAAG-30.
All si-RNAs were designed by Rosetta using a proprietary algorithm and were
synthesized by Sigma. SH-SY5Y cells were transiently transfected with two different
si-RNAs against human DAPK1 or scrambled si-RNA using Lipofectamine
RNAiMAX Reagent (Invitrogen) according to the manufacturer’s instructions. After
36 h of transfection, cells were harvested. For the neurite outgrowth assay, PC12
cells were also transiently transfected with a si-RNA against rat DAPK1 or
scrambled si-RNA using Lipofectamine 2000 (Invitrogen) for 36 h. The si-RNA target
sequences were as follows: human DAPK1-#1, 50-GAGAATCGATGTCCAGGA
T-30; human DAPK1-#2, 50-GACATGAAGGTACTTCGAA-30; rat DAPK1, 50-CC
AACAACGGGATCCTAGA-30; and scrambled si-RNA, 50-GATCATACGTGCGA
TCAGA-30. A scrambled si-RNA has no identity to any known gene sequence from
human, mouse, or rat in the BLAST database.
Quantitative RT-PCR assay for detection of the mRNA of tau
and DAPK1. Total RNA was isolated from SH-SY5Y cells or tissues of human
and mouse brain using an RNeasy Mini Kit or RNeasy Lipid Tissue Mini Kit
(Qiagen, Valencia, CA, USA), respectively, according to the manufacturer’s
instructions. cDNAs were synthesized using the iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA, USA). To determine mRNA levels of tau and DAPK1,
quantitative RT-PCR was performed on a Mastercycler ep realplex (Eppendorf,
Hauppauge, NY, USA) using a total volume of 20 ml containing 200 nM primers
and 1 AbsoluteTM Blue QPCR SYBR Green Mix (ABgene, Waltham, MA,
USA). For human tau amplification, primers htau-F (50-TGACACGG
ACGCTGGCCTGAA-30) and htau-R (50-CACTTGGAGGTCACCTTGCTC-30) were
used. For human DAPK1 amplification, primers hDAPK1-F (50-TCAAGACAGGC
ACGGCAAT-30) and hDAPK1-R (50-CCACCACGATAGGCATGTTG-30) were
used. For human 36B4 amplification, primers h36B4-F (50-AGATGCAGCAG
ATCCGCAT-30) and h36B4-R (50-GTTCTTGCCCATCAGCACC-30) were used.
For human 18S rRNA amplification, primers h18S rRNA-F (50-TGTCTCAAAGATT
AAGCCATGCA-30) and h18S rRNA-R (GCGACCAAAGGAACCATAACTG-30)
were used. For mouse tau amplification, primers mtau-F (50-TTCT
GTCCTCGCCTTCTGTC-30) and mtau-R (50-CTCCAGCATGGTCTTCCATT-30)
were used. For mouse 36B4 amplification, primers m36B4-F (50-TTTGCTGTACTG
ACTCGGTGA-30) and m36B4-R (50-CCTCCCACAACAAAACAACC-30) were used.
Measurement of Tau protein stability in cell culture / tissue
culture model. Tau protein half-life studies were performed by incubating cells
or tissues with CHX (10–75mg/ml) for the indicated time. The exogenous tau
protein stability was determined using HeLa, NIH3T3 carrying doxycycline-
inducible expression of pTRE-Tight or pTRE-Tight-DAPK1, NIH3T3 carrying stably
expressing Pin1 in combination with doxycycline-inducible expression of either
pTRE-Tight or pTRE-Tight-DAPK1 or pTRE-Tight-DAPK1K42A, WT MEF, DAPK1
KO MEF, and Pin1 KO MEF cells. The endogenous tau protein stability was
determined using SK-N-SH cells and primary cortical neurons and brain slices
prepared from WT and DAPK1 KO mice. The results from CHX experiments were
quantified by densitometry and analyzed using the ImageQuant software.
Primary cortical neuronal cell cultures in mice. DAPK1 KO mice
were described previously.57 Primary cultures of mouse embryonic cortical
neurons were prepared as described previously.58,59 Briefly, dissociated
embryonic neurons from embryonic day 16 (E16) WT and/or DAPK1 KO
C57BL/6 pregnant mice were resuspended in minimal essential medium
(Invitrogen) supplemented with 5% FBS, 5% horse serum, 100mM L-glutamine
(Invitrogen), and 28 mM D-glucose. Cells were plated onto poly-D-lysine-coated
6-well plates and maintained in a serum-free medium system consisting of
neurobasal media supplemented with B27 (Invitrogen) to inhibit glial proliferation.
Cortical neuronal cells were used for assaying endogenous tau protein stability (at
1 week) and neurite outgrowth (at 3 days).
Organotypic brain-slice cultures. Organotypic mouse brain-slice
cultures were performed as described previously38 with minor modifications.
Briefly, brains from 1- or 6-month-old mice were removed and cut into coronal
slices of 260-mm thickness with vibratome (Leica VT1200, Buffalo Grove, IL,
USA). Slices containing the hippocampus were used for endogenous tau protein
stability. The slices were cultured onto organotypic Millicell cell culture inserts
(Millipore, Billerica, MA, USA) in 6-well culture plates with culture medium.
Extraction of sarkosyl-insoluble tau. A sarkosyl-insoluble fraction was
prepared from mouse brain tissue as described previously38 with minor
modification. The brain tissue was homogenized in 5 volume of ice-cold lysis
buffer (10 mM Tris-HCl (pH 7.4), 0.8 M NaCl, 1 mM EGTA, 10% sucrose, 1 mM
DTT) supplemented with protease inhibitor cocktail and phosphatase inhibitor
cocktail and centrifuged at 20 000 g for 30 min at 4 1C. The supernatant was
collected and mixed to a final concentration of 1% (w/v) N-lauroylsarcosine and
incubated for 1 h at room temperature with constant shaking. After ultra-
centrifugation at 100 000 g for 1 h at 4 1C, the pellet containing sarkosyl-
insoluble, aggregated tau was resuspended in 50 mM Tris-HCl (pH 7.4) and
analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) for quantification of
phosphorylated tau protein.
Immunohistochemical detection of phosphorylation of tau and
Pin1. For immunohistochemical analysis of mouse brain tissues, WT and
DAPK1 KO mice were anesthetized and intracardially perfused with 4% PFA.
Immersion-fixed tissue sections were embedded in paraffin. Coronal tissue
sections were deparaffinized with xylene, rehydrated with descending grade of
ethanol, and incubated with 3% H2O2/PBS to quench the endogenous peroxidase
activity. After antigen retrieval, sections were incubated in PBS blocking buffer with
5% horse serum, 5% bovine serum albumin and 0.1% v/v Tween20. Primary
antibodies were added in blocking buffer and incubated with sections overnight at
4 1C. Secondary antibody was biotinylated goat-anti-rabbit IgG. Sections were
processed with ABC reagents by using a Vector ABC kit (Vector Laboratories,
Burlingame, CA, USA). After washing, the horseradish peroxidase (HRP) reaction
was detected with diaminobenzidine and H2O2. Positively stained areas were
quantified with ImageJ software.
Neurite outgrowth assay. To induce differentiation, PC12 cells plated onto
poly-L-lysine (Sigma)-coated 6-well in serum starved conditions (0.5% horse
serum and 0.25% FBS) were treated with 50 ng/ml NGF. Once cells developed
neurites after induction of differentiation, cells were fixed with 4% PFA for 15 min
at room temperature. The level of neurite outgrowth was quantified by counting the
number of PC12 cells bearing at least one neurite with a length equal to the cell
body diameter and by measuring the neurite length in random images from
triplicate experiments. Neurites were categorized by their length relative to the cell
body diameter as previously described.60 ‘L0’ means cells with no neurite, ‘L1’
means cells with neurites whose length is shorter than the cell body diameter, ‘L2’
means cells with neurites whose length is between the original and twice the cell
body diameter, and ‘L3’ means cells with neurites whose length is longer than
twice the cell body diameter.
In vivo MT assembly assay. PC12 cells were exposed to paclitaxel
(0.2mM), nocodazole (2 mM), and DAPK1 inhibitor (70-, 100 nM) for 12 h. After
treatment, cells were harvested and lysed at 37 1C for 5 min with hypotonic buffer
(1 mM MgCl2, 2 mM EGTA, 0.5% NP-40, 20 mM Tris-HCl (pH 6.8)) supplemented
with protease inhibitor cocktail. The cell lysates were centrifuged at 18 000 g for
10 min at 25 1C. The supernatants containing the unpolymerized (soluble) tubulin
were transferred to a fresh tube. The pellets containing the polymerized (insoluble)
tubulin were resuspended in an equal amount of hypotonic buffer and sonicated
on ice for 2 min. Protein samples (10 mg) of the two fractions were separated by
SDS-PAGE. The tubulin signals were quantified by densitometry and analyzed
using the ImageQuant software.
Immunoblot analysis. After harvesting, the cells were lysed in ice-cold lysis
buffer (50 mM Tris-HCl (pH 7.4), 50 mM NaCl, 1 mM EGTA, 1% Triton X-100,
1 mM DTT) supplemented with protease inhibitor cocktail and phosphatase
inhibitor cocktail. Mouse and human brain extracts were prepared by
homogenizing tissue in ice-cold lysis buffer (10 mM Tris-HCl (pH 7.4), 0.8 M
NaCl, 1 mM EGTA, 10% sucrose, 1 mM DTT) supplemented with protease
inhibitor cocktail and phosphatase inhibitor cocktail. The soluble protein
concentration was determined by Bradford assay (Bio-Rad). Protein samples
(5–10mg) were separated by SDS-PAGE and transferred to polyvinylidene fluoride
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membranes (PerkinElmer, Waltham, MA, USA). The membranes were then probed
with various antibodies, followed by HRP-conjugated secondary antibodies.
Antibody-bound proteins were detected using the Western Lightning Plus-ECL
(PerkinElmer) or ECL Prime (GE Healthcare Life Sciences, Pittsburgh, PA, USA)
chemiluminescence system. The following antibodies were used to probe different
proteins: Flag, DAPK1 (Sigma); DCX, b-actin, a-tubulin (Cell Signaling Technology,
Danvers, MA, USA); PHF-13 (p-Ser396-Tau) (Anaspec, Fremont, CA, USA); Tau-5,
p-Tau (Ser262); and AT180 (pThr231-Tau) (Invitrogen).
Brain samples. Whole-brain tissues from mice at different ages (1–22 month)
were harvested for the comparison between WT and DAPK1 KO littermates. After
extraction, whole brains were snap frozen in liquid nitrogen-cold isopentane and
stored at  80 1C until use. Total brain lysates and sarkosyl-insoluble fractions
were obtained from these mouse brain tissues. Brain hippocampus tissues of
human Alzheimer’s patients and controls were obtained from the Neuropathology
Core of the Massachusetts Alzheimer’s Disease Research Center (Boston, MA,
USA) and the Harvard Brain Tissue Resource Center (Boston, MA, USA).
Research was conducted in compliance with the policies and principles contained
in the Federal Policy for the Protection of Human subjects. In most cases, brain
hippocampus tissues obtained within 30 h postmortem were used; 12 from
individuals with a clinical diagnosis of probable AD and 12 from individual without
any neurological disorder (Supplementary Table S1).
Statistical analysis. The data are presented as means±standard error
(S.E.) of the three independent experiments. Statistical significances were
calculated by one-way analysis of variance (ANOVA) followed by Dunnett’s
multiple comparison post hoc test using SAS 8.1 software for Windows (SAS
Institute), with P-values o0.05 considered to be statistically significant.
Study approval. All studies were carried out following the guidelines set by
Beth Israel Deaconess Medical Center’s Institutional Animal Care and Use
Committee in accordance with the Association for Assessment and Accreditation
of Laboratory Animal Care International regulations.
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